Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.

Journal of cancer research and clinical oncology - 1 Dec 2023

Huang Fang, Cui Jian, Wan Jingxuan, Yuan Xue, Zhu Yuanzhe, Wu Xiangxiang, Zuo Wei, Zhao Tiantian

Abstract excerpt

PURPOSE: Epidermal growth factor receptor (EGFR) mutation is a prominent driver of lung cancer. Tyrosine kinase inhibitors (TKIs) have shown efficacy in treating EGFR-mutant lung cancer, but the emergence of drug resistance poses a significant challenge. Recent research has highlighted solute carrier family 12 member 8 (SLC12A8) as one of the highly upregulated genes in various cancer types. However, its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Sodium-Potassium-Chloride Symporters

Source

Identifiers

PMID: 37725242
DOI: 10.1007/s00432-023-05416-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.PMID 37725242Read ↗

SLC2A1 promotes chemo-immunotherapy resistance in lung adenocarcinoma by modulating the AKT signaling pathwaySemantic proximity Read ↗

EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.Semantic proximity Read ↗

Identification of biomarkers, pathways and potential therapeutic targets for EGFR-TKI resistance in non-small-cell lung cancerSemantic proximity Read ↗

Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma.Semantic proximity Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations.Semantic proximity Read ↗

The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.Semantic proximity Read ↗

A Novel TP53 Gene Mutation Sustains Non-Small Cell Lung Cancer through Mitophagy.Semantic proximity Read ↗

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.Semantic proximity Read ↗

Longitudinal single-cell RNA model aids prediction of EGFR-TKI resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.